Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -6.40M | -23.33M | -3.71M | -64.38M | -40.14M |
| Total Depreciation and Amortization | 325.00K | 331.00K | 334.00K | 352.00K | 612.00K |
| Total Amortization of Deferred Charges | 147.00K | 121.00K | 152.00K | 150.00K | 143.00K |
| Total Other Non-Cash Items | -18.68M | -2.87M | -25.01M | 39.06M | 9.32M |
| Change in Net Operating Assets | 3.91M | -3.92M | -2.86M | 6.26M | -1.79M |
| Cash from Operations | -20.69M | -29.67M | -31.10M | -18.56M | -31.86M |
| Capital Expenditure | -- | -- | -- | -38.00K | 0.00 |
| Sale of Property, Plant, and Equipment | 0.00 | 96.00K | 29.00K | 1.56M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 24.97M | -24.67M | 0.00 | 28.64M |
| Cash from Investing | 0.00 | 25.07M | -24.64M | 1.52M | 28.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -3.00K | -5.00K |
| Issuance of Common Stock | 0.00 | 115.00K | -- | 43.38M | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -74.00K | -265.00K | -- | -- |
| Cash from Financing | 0.00 | 41.00K | -265.00K | 43.38M | -5.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.69M | -4.56M | -56.00M | 26.34M | -3.22M |